References: CDTI IDI-20220676 CTA 22/1075

Date: 03/12/2021 to 31/12/2023

The objective of the project is to develop new recombinant antibodies with greater specificity and sensitivity than the current A1 and G12 antibodies, as well as a cellular platform for their production, to expand the product catalog of the iVYDAL In Vitro Diagnostics® line and develop an automated process for detecting gluten immunogenic peptides (GIP) in urine for routine application in the clinical sector. Additionally, to analyze the therapeutic potential of recombinant antibodies to neutralize GIP and prevent immune response in samples from patients with celiac disease.